GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 482
- Registration Number
- NCT01252940
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸Capital Medical Associates PC, Washington, District of Columbia, United States
🇦🇹Univ.-Kklinik fuer Innere Medizin III, Salzberg, Austria
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- Drug: GS-9190 placeboBiological: Pegasys®
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 324
- Registration Number
- NCT01225380
- Locations
- 🇺🇸
UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸Medical Associates Research Group, San Diego, California, United States
Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
- Conditions
- Myocardial Perfusion ImagingMyocardial Ischemia
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 81
- Registration Number
- NCT01221272
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇨🇦Chum Hotel Dieu, Montreal, Quebec, Canada
🇫🇮Turku University Hospital, Turku, Finland
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 105
- Registration Number
- NCT01203930
- Locations
- 🇺🇸
University of California, San Diego, Moores Cancer Center, La Jolla, California, United States
🇺🇸Columbia University - Herbert Irving Pavilion, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 71
- Registration Number
- NCT01193478
Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 147
- Registration Number
- NCT01188772
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dr. Bruce Bacon, St. Louis, Missouri, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Ranolazine in Diastolic Heart Failure
- Conditions
- Diastolic Heart Failure
- Interventions
- Other: Saline 0.9% and placebo tablet
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT01163734
- Locations
- 🇩🇪
University Medicine Goettingen (UMG), Goettingen, Germany
Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT01163721
- Locations
- 🇺🇸
National Research Institute (NRI), Los Angeles, California, United States
🇺🇸Vince and Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸Cetero Research, San Antonio, Texas, United States
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- HIVHIV Infections
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 698
- Registration Number
- NCT01108510
- Locations
- 🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸Oasis Clinic, Los Angeles, California, United States
🇺🇸Peter J Ruane, MD, Inc, Los Angeles, California, United States
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
- Conditions
- HIVHIV Infections
- Interventions
- Drug: ATVDrug: ATV PlaceboDrug: FTC/TDFDrug: FTC/TDF Placebo
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 708
- Registration Number
- NCT01106586
- Locations
- 🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸Ruth M. Rothstein CORE Center, Chicago, Illinois, United States
🇺🇸The Stamford Hospital, Stamford, Connecticut, United States